多発性がん早期発見の世界市場：市場規模・シェア・動向分析 (種類別・最終用途別・地域別・セグメント別、2025年～2030年)

多発性がん早期発見 (MCED) 市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の多発性がん早期発見の市場規模は、2025年から2030年にかけてCAGR 17%を記録し、2030年までに28億6,000万米ドルに達すると予測されています。

適切な治療が行えるようにがんを早期に発見する効果的な方法を提供する必要性と、がんの有病率の上昇と複数の病型が市場の成長を促進すると予想されています。早期発見診断への要求は、簡単な疾病管理を容易にし、その後の死亡率を低下させ、市場全体を牽引しています。

多発性がん早期発見 (MCED) 検査は、患者が無症状の場合でも体内の腫瘍を発見できるように設計されています。がんに罹患している可能性が高いかどうかを判断するために、複数のシグナルを同時に評価します。がんを早期に発見するための検査は数多く開発されていますが、MCEDスクリーニング検査は、米国ではつい最近、ラボで開発された検査として初めて実用化されました。例えば、2022年7月、GRAIL社のGalleriがセントルイスのマーシーでLDTとして利用可能になりました。さらに、MCEDスクリーニング検査はExact SciencesとFreenomeによって開発されており、GRAILのGalleri検査は、最大50の異なる型を検出できるとして、保険適用外で販売されています。

研究によると、MCED検査は、治療可能で時には治癒も可能な早期ステージを検出するよりも、後期ステージや進行ステージを検出する感度が高いです。さらに、この検査は特異性が高く、がんでない人が陽性となる可能性は極めて低いことが判明しました。早期診断の需要に応えるため、MCEDの開発分野では現在も研究が続けられています。

市場の大手企業は、2、3種類のがんから50種類のがんまで識別できると主張しています。各社は、こうしたスクリーニング検査の成長と開発、そして迅速な商品化に注力しています。例えば、2020年12月、Singlera GenomicsはMCED検査の開発、マーケティング、プロモーションのためにシリーズBで1億5,000万米ドルの資金を調達しました。GRAILはPoint32Healthとパイロットプロジェクトを開始し、Point32HealthはMCED検査を含む最初の健康向け商業プランとなりました。

多発性がん早期発見市場：分析概要

• 遺伝子パネル、LDT、その他セグメントが市場をリードし、2024年には91.28%のシェアを占めました。同分野の成長は、診断ラボでのLDT利用にFDA承認が不要であることに起因します。
• リキッドバイオプシー分野は予測期間中最も速いCAGRで成長すると予測されています。このセグメントの成長は、新しい検査開発のために投資家から資金提供を受けるプレーヤーが増加していることに起因しています。
• 病院の最終用途セグメントは2024年に48.44%のシェアで市場をリードしました。これは、一つ屋根の下で様々なサービスが受けられるため、病院での治療が好まれるようになっていることに起因しています。
• アジア太平洋の多発性がん早期発見市場は、医療インフラの大幅な改善、人口の増加、市場参入する現地企業の増加により、予測期間中に最も速いCAGRを記録すると予測されています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 多発性がん早期発見 (MCED) 市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 多発性がん早期発見 (MCED) 市場の分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 多発性がん早期発見 (MCED) 市場：種類別の推定と動向分析

• 市場シェア：種類別 (2024年・2030年)
• セグメントダッシュボード
• 世界の多発性がん早期発見 (MCED) 市場の展望：種類別
• 市場規模の予測と動向分析 (2018年～2030年)
• 液体生検
• 遺伝子パネル、LDT、その他

第5章 多発性がん早期発見 (MCED) 市場：最終用途別の推定と動向分析

• 市場シェア：最終用途別 (2024年・2030年)
• セグメントダッシュボード
• 世界の多発性がん早期発見 (MCED) 市場の展望：最終用途別
• 市場規模の予測と動向分析 (2018年～2030年)
• 病院
• 診断検査室
• その他

第6章 多発性がん早期発見 (MCED) 市場：地域別の推定と動向分析

• 市場シェア：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 市場規模の予測と動向分析 (2018年～2030年)
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 最近の動向と影響分析：主な市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2024
  • Illumina, Inc. (GRAIL, LLC)
  • GRAIL, Inc.
  • Exact Sciences Corporation
  • FOUNDATION MEDICINE, INC.
  • AnchorDx
  • Guardant Health
  • Burning Rock Biotech Limited
  • GENECAST
  • Beijing Lyman Juntai International Medical Technology Development Co.
  • Freenome Holdings, Inc.
  • Elypta AB

List of Tables

• Table 1 List of abbreviation
• Table 2 North America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
• Table 3 North America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 4 North America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 5 U.S. multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 6 U.S. multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 7 Canada multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 8 Canada multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 9 Mexico multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 10 Mexico multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 11 Europe multi cancer early detection market, by region, 2018 - 2030 (USD Million)
• Table 12 Europe multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 13 Europe multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 14 Germany multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 15 Germany multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 16 UK multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 17 UK multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 18 France multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 19 France multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 20 Italy multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 21 Italy multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 22 Spain multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 23 Spain multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 24 Denmark multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 25 Denmark multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 26 Sweden multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 27 Sweden multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 28 Norway multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 29 Norway multi cancer early detection market, by end use, 2018 - 2030 (USD Million)Asia Pacific multi cancer early detection market, by region, (USD Million) 2018 - 2030 (USD Million)
• Table 30 Asia Pacific multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 31 China multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 32 China multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 33 Japan multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 34 Japan multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 35 India multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 36 India multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 37 South Korea multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 38 South Korea multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 39 Australia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 40 Australia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 41 Thailand multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 42 Thailand multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 43 Latin America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
• Table 44 Latin America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 45 Latin America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 46 Brazil multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 47 Brazil multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 48 Argentina multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 49 Argentina multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 50 MEA multi cancer early detection market, by region, 2018 - 2030 (USD Million)
• Table 51 MEA multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 52 MEA multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 53 South Africa multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 54 South Africa multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 55 Saudi Arabia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 56 Saudi Arabia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 57 UAE multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 58 UAE multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
• Table 59 Kuwait multi cancer early detection market, by type, 2018 - 2030 (USD Million)
• Table 60 Kuwait multi cancer early detection market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Multi cancer early detection market: market outlook
• Fig. 14 Tumor ablation competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Multi cancer early detection market driver impact
• Fig. 20 Multi cancer early detection market restraint impact
• Fig. 21 Multi cancer early detection market strategic initiatives analysis
• Fig. 22 Multi cancer early detection market: Type movement analysis
• Fig. 23 Multi cancer early detection market: Type outlook and key takeaways
• Fig. 24 Liquid biopsy market estimates and forecast, 2018 - 2030
• Fig. 25 Gene panel, LDT, & others estimates and forecast, 2018 - 2030
• Fig. 26 Multi cancer early detection market: End Use movement Analysis
• Fig. 27 Multi cancer early detection market: End Use outlook and key takeaways
• Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030
• Fig. 29 Diagnostic laboratories market estimates and forecasts, 2018 - 2030
• Fig. 30 Others market estimates and forecasts,2018 - 2030
• Fig. 31 Global multi cancer early detection market: Regional movement analysis
• Fig. 32 Global multi cancer early detection market: Regional outlook and key takeaways
• Fig. 33 Global multi cancer early detection market share and leading players
• Fig. 34 North America market share and leading players
• Fig. 35 Europe market share and leading players
• Fig. 36 Asia Pacific market share and leading players
• Fig. 37 Latin America market share and leading players
• Fig. 38 Middle East & Africa market share and leading players
• Fig. 39 North America: SWOT
• Fig. 40 Europe SWOT
• Fig. 41 Asia Pacific SWOT
• Fig. 42 Latin America SWOT
• Fig. 43 MEA SWOT
• Fig. 44 North America, by country
• Fig. 45 North America
• Fig. 46 North America market estimates and forecasts, 2018 - 2030
• Fig. 47 U.S.
• Fig. 48 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 49 Canada
• Fig. 50 Canada market estimates and forecasts, 2018 - 2030
• Fig. 51 Mexico
• Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 53 Europe
• Fig. 54 Europe market estimates and forecasts, 2018 - 2030
• Fig. 55 UK
• Fig. 56 UK market estimates and forecasts, 2018 - 2030
• Fig. 57 Germany
• Fig. 58 Germany market estimates and forecasts, 2018 - 2030
• Fig. 59 France
• Fig. 60 France market estimates and forecasts, 2018 - 2030
• Fig. 61 Italy
• Fig. 62 Italy market estimates and forecasts, 2018 - 2030
• Fig. 63 Spain
• Fig. 64 Spain market estimates and forecasts, 2018 - 2030
• Fig. 65 Denmark
• Fig. 66 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 67 Sweden
• Fig. 68 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 69 Norway
• Fig. 70 Norway market estimates and forecasts, 2018 - 2030
• Fig. 71 Asia Pacific
• Fig. 72 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 73 China
• Fig. 74 China market estimates and forecasts, 2018 - 2030
• Fig. 75 Japan
• Fig. 76 Japan market estimates and forecasts, 2018 - 2030
• Fig. 77 India
• Fig. 78 India market estimates and forecasts, 2018 - 2030
• Fig. 79 Thailand
• Fig. 80 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 81 South Korea
• Fig. 82 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 83 Australia
• Fig. 84 Australia market estimates and forecasts, 2018 - 2030
• Fig. 85 Latin America
• Fig. 86 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 87 Brazil
• Fig. 88 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 89 Argentina
• Fig. 90 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 91 Middle East and Africa
• Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 93 South Africa
• Fig. 94 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 95 Saudi Arabia
• Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 97 UAE
• Fig. 98 UAE market estimates and forecasts, 2018 - 2030
• Fig. 99 Kuwait
• Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 101 Market share of key market players - Multi cancer early detection market

Multi Cancer Early Detection Market Growth & Trends:

The global multi cancer early detection market size is expected to reach USD 2.86 billion by 2030, registering a CAGR of 17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The need for providing effective ways to detect cancer at an early stage so that the right treatment can be given and the rising prevalence of cancer and multiple forms are expected to fuel the growth of the market. The requirement for early detection diagnostics, which facilitates simple disease management and subsequently lowers the death rate, drives the overall market.

Multi cancer early detection (MCED) tests are designed to find tumors in the body even when a patient is asymptomatic. To determine whether there is a high probability that a person has cancer, they simultaneously evaluate several signals. Although numerous tests are being developed to detect cancer at an early stage, the first MCED screening test was just recently made available in the U.S. as a lab-developed test. For instance, in July 2022, GRAIL's Galleri was made available as an LDT at Mercy, St. Louis. Furthermore, MCED screening tests are being developed by Exact Sciences and Freenome, and GRAIL's Galleri test is being marketed without payer coverage with the claim that it can detect up to fifty different forms.

Studies show that MCED tests have a higher sensitivity for detecting later-stage or advanced than for detecting earlier stages, which are more treatable and occasionally curable. Additionally, it was found that the tests were highly specific, which made it extremely unlikely that they would give a positive result for someone who did not have cancer. To meet the demand for early diagnosis, ongoing research is still being done in the field of developing MCED.

The major players in the market assert that they can identify as few as two or three different cancer types or as many as fifty. They are focusing on the growth and development of these screening tests and faster commercialization. For instance, in December 2020, Singlera Genomics raised $150 million in Series B funding for the development, marketing, and promotion of its MCED tests. GRAIL launched a pilot project with Point32Health, making Point32Health the first commercial plan for health to include MCED tests.

Multi Cancer Early Detection Market Report Highlights:

• The gene panel, LDT, & others segment led the market and accounted for a share of 91.28% in 2024. The growth of the segment is attributed to the non-requirement of FDA approval for the utilization of LDT in diagnostic laboratories.
• The liquid biopsy segment is anticipated to grow at the fastest CAGR over the forecast period. The growth of this segment is attributed to the increasing number of players receiving funding from investors for the development of new tests.
• The hospitals end-use segment led the market with a share of 48.44% in 2024. This is attributed to the growing preference of hospitals for care due to the availability of various services under one roof.
• Asia Pacific multi cancer early detection market is anticipated to witness the fastest CAGR over the forecast period due to a significantly improving healthcare infrastructure, a growing population, and a rising number of local companies entering the market

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Multi Cancer Early Detection (MCED) Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Extensive R&D for the development of MCED
    • 3.2.1.3. Need to develop diagnostic options that can detect cancer at an early stage
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Collection of adequate safety and efficacy data for regulatory approval
• 3.3. Multi Cancer Early Detection (MCED) Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Multi Cancer Early Detection (MCED) Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Multi Cancer Early Detection (MCED) Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Liquid Biopsy
  • 4.5.1. Liquid biopsy market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Gene Panel, LDT, and Others
  • 4.6.1. Gene panel, LDT, and others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Multi Cancer Early Detection (MCED) Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Multi Cancer Early Detection (MCED) Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Hospitals
  • 5.5.1. Hospitals market estimates and forecasts 2018 - 2030 (USD million)
• 5.6. Diagnostic Laboratories
  • 5.6.1. Diagnostic laboratories market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Other
  • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Multi Cancer Early Detection (MCED) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. Illumina, Inc. (GRAIL, LLC)
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. GRAIL, Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Exact Sciences Corporation
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. FOUNDATION MEDICINE, INC.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. AnchorDx
    • 7.3.8.1. Company overview
    • 7.3.8.2. Product benchmarking
    • 7.3.8.3. Strategic initiatives
  • 7.3.9. Guardant Health
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Burning Rock Biotech Limited
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. GENECAST
    • 7.3.11.1. Company overview
    • 7.3.11.2. Product benchmarking
    • 7.3.11.3. Strategic initiatives
  • 7.3.12. Beijing Lyman Juntai International Medical Technology Development Co.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Product benchmarking
    • 7.3.12.3. Strategic initiatives
  • 7.3.13. Freenome Holdings, Inc.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Product benchmarking
    • 7.3.13.3. Strategic initiatives
  • 7.3.14. Elypta AB
    • 7.3.14.1. Company overview
    • 7.3.14.2. Product benchmarking
    • 7.3.14.3. Strategic initiatives